[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist]. - Suppr

Suppr

超能文献

[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].

作者信息

Alban Susanne

机构信息

Pharmazeutisches Institut, Christian-Albrechts-Universität, Gutenbergstr. 76, 24118 Kiel.

出版信息

Pharm Unserer Zeit. 2009;38(4):320-8. doi: 10.1002/pauz.200900321.

DOI:10.1002/pauz.200900321

PMID:19572350

Abstract

摘要

相似文献

[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].

Pharm Unserer Zeit. 2009;38(4):320-8. doi: 10.1002/pauz.200900321.

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

Clin Appl Thromb Hemost. 2010 Apr;16(2):170-6. doi: 10.1177/1076029609355589.

Prasugrel (Effient) vs. clopidogrel (Plavix).

Med Lett Drugs Ther. 2009 Sep 7;51(1320):69-70.

Platelet P2 receptors: old and new targets for antithrombotic drugs.

Expert Rev Cardiovasc Ther. 2007 Jan;5(1):45-55. doi: 10.1586/14779072.5.1.45.

Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.

Expert Rev Cardiovasc Ther. 2009 Apr;7(4):361-9. doi: 10.1586/erc.09.4.

Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.

Expert Opin Investig Drugs. 2011 Jan;20(1):119-33. doi: 10.1517/13543784.2010.538381. Epub 2010 Dec 13.

ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.

J Cardiothorac Vasc Anesth. 2013 Aug;27(4):779-95. doi: 10.1053/j.jvca.2012.11.014. Epub 2013 May 3.

Future of oral antiplatelet therapy: four challenged hypotheses.

Thromb Haemost. 2009 Jun;101(6):1041-3.

Prasugrel: a novel platelet ADP P2Y receptor antagonist.

Cardiovasc Ther. 2009 Fall;27(3):194-8. doi: 10.1111/j.1755-5922.2009.00086.x.

Prasugrel.

Circulation. 2010 Jul 27;122(4):394-403. doi: 10.1161/CIRCULATIONAHA.109.921502.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].

Pharm Unserer Zeit. 2009;38(4):320-8. doi: 10.1002/pauz.200900321.

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

Clin Appl Thromb Hemost. 2010 Apr;16(2):170-6. doi: 10.1177/1076029609355589.

Prasugrel (Effient) vs. clopidogrel (Plavix).

Med Lett Drugs Ther. 2009 Sep 7;51(1320):69-70.

Platelet P2 receptors: old and new targets for antithrombotic drugs.

Expert Rev Cardiovasc Ther. 2007 Jan;5(1):45-55. doi: 10.1586/14779072.5.1.45.

Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.

Expert Rev Cardiovasc Ther. 2009 Apr;7(4):361-9. doi: 10.1586/erc.09.4.

Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.

Expert Opin Investig Drugs. 2011 Jan;20(1):119-33. doi: 10.1517/13543784.2010.538381. Epub 2010 Dec 13.

ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.

J Cardiothorac Vasc Anesth. 2013 Aug;27(4):779-95. doi: 10.1053/j.jvca.2012.11.014. Epub 2013 May 3.

Future of oral antiplatelet therapy: four challenged hypotheses.

Thromb Haemost. 2009 Jun;101(6):1041-3.

Prasugrel: a novel platelet ADP P2Y receptor antagonist.

Cardiovasc Ther. 2009 Fall;27(3):194-8. doi: 10.1111/j.1755-5922.2009.00086.x.

Prasugrel.

Circulation. 2010 Jul 27;122(4):394-403. doi: 10.1161/CIRCULATIONAHA.109.921502.